Literature DB >> 15016866

Alternative approaches for efficient inhibition of hepatitis C virus RNA replication by small interfering RNAs.

Jan Krönke1, Ralf Kittler, Frank Buchholz, Marc P Windisch, Thomas Pietschmann, Ralf Bartenschlager, Michael Frese.   

Abstract

Persistent infection with hepatitis C virus (HCV) is a leading cause of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. It has recently been shown that HCV RNA replication is susceptible to small interfering RNAs (siRNAs), but the antiviral activity of siRNAs depends very much on their complementarity to the target sequence. Thus, the high degree of sequence diversity between different HCV genotypes and the rapid evolution of new quasispecies is a major problem in the development of siRNA-based gene therapies. For this study, we developed two alternative strategies to overcome these obstacles. In one approach, we used endoribonuclease-prepared siRNAs (esiRNAs) to simultaneously target multiple sites of the viral genome. We show that esiRNAs directed against various regions of the HCV coding sequence as well as the 5' nontranslated region (5' NTR) efficiently block the replication of subgenomic and genomic HCV replicons. In an alternative approach, we generated pseudotyped retroviruses encoding short hairpin RNAs (shRNAs). A total of 12 shRNAs, most of them targeting highly conserved sequence motifs within the 5' NTR or the early core coding region, were analyzed for their antiviral activities. After the transduction of Huh-7 cells containing a subgenomic HCV replicon, we found that all shRNAs targeting sequences in domain IV or nearby coding sequences blocked viral replication. In contrast, only one of seven shRNAs targeting sequences in domain II or III had a similar degree of antiviral activity, indicating that large sections of the NTRs are resistant to RNA interference. Moreover, we show that naive Huh-7 cells that stably expressed certain 5' NTR-specific shRNAs were largely resistant to a challenge with HCV replicons. These results demonstrate that the retroviral transduction of HCV-specific shRNAs provides a new possibility for antiviral intervention.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15016866      PMCID: PMC371081          DOI: 10.1128/jvi.78.7.3436-3446.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  73 in total

1.  Asymmetry in the assembly of the RNAi enzyme complex.

Authors:  Dianne S Schwarz; György Hutvágner; Tingting Du; Zuoshang Xu; Neil Aronin; Phillip D Zamore
Journal:  Cell       Date:  2003-10-17       Impact factor: 41.582

2.  Functional siRNAs and miRNAs exhibit strand bias.

Authors:  Anastasia Khvorova; Angela Reynolds; Sumedha D Jayasena
Journal:  Cell       Date:  2003-10-17       Impact factor: 41.582

3.  The activity of siRNA in mammalian cells is related to structural target accessibility: a comparison with antisense oligonucleotides.

Authors:  Rosel Kretschmer-Kazemi Far; Georg Sczakiel
Journal:  Nucleic Acids Res       Date:  2003-08-01       Impact factor: 16.971

4.  Different thermostabilities of FLP and Cre recombinases: implications for applied site-specific recombination.

Authors:  F Buchholz; L Ringrose; P O Angrand; F Rossi; A F Stewart
Journal:  Nucleic Acids Res       Date:  1996-11-01       Impact factor: 16.971

5.  Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line.

Authors:  J P Morgenstern; H Land
Journal:  Nucleic Acids Res       Date:  1990-06-25       Impact factor: 16.971

6.  Site-directed mutagenesis by overlap extension using the polymerase chain reaction.

Authors:  S N Ho; H D Hunt; R M Horton; J K Pullen; L R Pease
Journal:  Gene       Date:  1989-04-15       Impact factor: 3.688

7.  Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system.

Authors:  R B DuBridge; P Tang; H C Hsia; P M Leong; J H Miller; M P Calos
Journal:  Mol Cell Biol       Date:  1987-01       Impact factor: 4.272

8.  Specific inhibition of hepatitis C virus expression by antisense oligodeoxynucleotides. In vitro model for selection of target sequence.

Authors:  T Wakita; J R Wands
Journal:  J Biol Chem       Date:  1994-05-13       Impact factor: 5.157

9.  Nucleotide sequence and mutation rate of the H strain of hepatitis C virus.

Authors:  N Ogata; H J Alter; R H Miller; R H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

10.  Genetic drift of hepatitis C virus during an 8.2-year infection in a chimpanzee: variability and stability.

Authors:  H Okamoto; M Kojima; S Okada; H Yoshizawa; H Iizuka; T Tanaka; E E Muchmore; D A Peterson; Y Ito; S Mishiro
Journal:  Virology       Date:  1992-10       Impact factor: 3.616

View more
  59 in total

1.  RNA interference against animal viruses: how morbilliviruses generate extended diversity to escape small interfering RNA control.

Authors:  Carine L Holz; Emmanuel Albina; Cécile Minet; Renaud Lancelot; Olivier Kwiatek; Geneviève Libeau; Renata Servan de Almeida
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

2.  RNA interference with measles virus N, P, and L mRNAs efficiently prevents and with matrix protein mRNA enhances viral transcription.

Authors:  Thorsten Reuter; Benedikt Weissbrich; Sibylle Schneider-Schaulies; Jürgen Schneider-Schaulies
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

3.  Silencing of hepatitis A virus infection by small interfering RNAs.

Authors:  Yuri Kusov; Tatsuo Kanda; Ann Palmenberg; Jean-Yves Sgro; Verena Gauss-Müller
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

Review 4.  RNA interference and antiviral therapy.

Authors:  Yan Ma; Chu-Yan Chan; Ming-Liang He
Journal:  World J Gastroenterol       Date:  2007-10-21       Impact factor: 5.742

Review 5.  New therapeutic opportunities for hepatitis C based on small RNA.

Authors:  Qiu-Wei Pan; Scot D Henry; Bob J Scholte; Hugo W Tilanus; Harry L A Janssen; Luc J W van der Laan
Journal:  World J Gastroenterol       Date:  2007-09-07       Impact factor: 5.742

6.  RNA interference with special reference to combating viruses of crustacea.

Authors:  Kathy La Fauce; Leigh Owens
Journal:  Indian J Virol       Date:  2012-08-14

7.  The level of CD81 cell surface expression is a key determinant for productive entry of hepatitis C virus into host cells.

Authors:  George Koutsoudakis; Eva Herrmann; Stephanie Kallis; Ralf Bartenschlager; Thomas Pietschmann
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

8.  Small interfering RNA targeted to hepatitis C virus 5' nontranslated region exerts potent antiviral effect.

Authors:  Tatsuo Kanda; Robert Steele; Ranjit Ray; Ratna B Ray
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

9.  Class III phosphatidylinositol 4-kinase alpha and beta are novel host factor regulators of hepatitis C virus replication.

Authors:  Jason Borawski; Philip Troke; Xiaoling Puyang; Veronica Gibaja; Shanchaun Zhao; Craig Mickanin; Juliet Leighton-Davies; Christopher J Wilson; Vic Myer; Ivan Cornellataracido; Jeremy Baryza; John Tallarico; Gerard Joberty; Marcus Bantscheff; Markus Schirle; Tewis Bouwmeester; Joanna E Mathy; Kai Lin; Teresa Compton; Mark Labow; Brigitte Wiedmann; L Alex Gaither
Journal:  J Virol       Date:  2009-07-15       Impact factor: 5.103

10.  Sigma-1 receptor regulates early steps of viral RNA replication at the onset of hepatitis C virus infection.

Authors:  Martina Friesland; Lidia Mingorance; Josan Chung; Francis V Chisari; Pablo Gastaminza
Journal:  J Virol       Date:  2013-03-27       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.